Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database

References

• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Trněný M, Vášová I, Pytlík R, et al. The non-Hodgkin's lymphoma subtypes distribution and survival in the Czech Republic. Klinicka Onkologie. 2007;20:341–348.
   Google Scholar
• Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23:5019–5026.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Cheson BD. How we manage follicular lymphoma. Leukemia. 2014;28:1388–1395.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Marcus R, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii76–iii82.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Wierda WG, et al. Non-Hodgkin’s lymphomas, version 4.2014. J Natl Compr Canc Netw. 2014;12:1282–1303.
   PubMed Web of Science ®Google Scholar
• Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31:1506–1513.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–1210.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42–51.
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516–2522.
   PubMed Web of Science ®Google Scholar
• Smith SM. Dissecting follicular lymphoma: high versus low risk. Hematology Am Soc Hematol Educ Program. 2013;2013:561–567.
   PubMedGoogle Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• van de Schans SA, Steyerberg EW, Nijziel MR, et al. Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. Ann Oncol. 2009;20:1697–1702.
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504–1508.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555–4562.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Merli M, Passamonti F, et al. Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haematol. 2010;149:455–457.
   PubMed Web of Science ®Google Scholar
• Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 2006;108:2540–2544.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:2667–2674.
   PubMed Web of Science ®Google Scholar
• Brown JR, Feng Y, Gribben JG, et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant. 2007;13:1057–1065.
   PubMed Web of Science ®Google Scholar
• Wang B, Ren C, Zhang W, et al. Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis. Hematol Oncol. 2013;31:29–33.
   PubMed Web of Science ®Google Scholar
• Khabori M, de Almeida JR, Guyatt GH, et al. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2012;104:18–28.
   PubMedGoogle Scholar
• Schaaf M, Reiser M, Borchmann P, et al. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. Cochrane Database Syst Rev. 2012;1:CD007678.
   PubMedGoogle Scholar
• Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111:4004–4013.
   PubMed Web of Science ®Google Scholar
• Decaudin D, Lepage E, Brousse N, et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients – a study of the groupe d'Etude des lymphomes de l’Adulte. J Clin Oncol. 1999;17:2499–2505.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2008.
   Google Scholar
• LYMABOL-1: Detail of the clinical trial [Internet], Prague, Czech Republic: State Institute for Drug Control [cited 2016 Feb 12]. Available from: http://www.sukl.eu/modules/evaluation/detail.php?id =16212.
   Google Scholar
• Colombat P, Biron P, Laporte JP, et al. BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin’s lymphomas. Eur J Cancer. 1990;26:858.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–1006.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244
   PubMed Web of Science ®Google Scholar
• Papajík T, Jedlicková K, Kriegová E, et al. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up. Neoplasma. 2001;48:501–505.
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Carlotti E, Oldani E, et al. Quantitative PCR of bone marrow BCL2/IgH + cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood. 2005;105:3428–3433.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, De Guibert S, Planche L, et al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica. 2011;96:1128–1135.
   PubMed Web of Science ®Google Scholar
• Berinstein Bhella Pennell, et al. Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab. Ann Hematol. 2015;94:813–823.
   PubMed Web of Science ®Google Scholar
• Montoto S, Corradini P, Dreyling M, et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica. 2013;98:1014–1021.
   PubMed Web of Science ®Google Scholar
• Schouten HC. What is the role of stem-cell transplantation for follicular non-Hodgkin lymphoma in the rituximab era? J Clin Oncol. 2013;31:1617–1618.
   PubMed Web of Science ®Google Scholar
• Bhatt VR, Armitage JO. Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma. Expert Opin Biol Ther. 2015;29:1–10.
   Google Scholar
• Arcaini L, Morello L, Tucci A, et al. Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. Am J Hematol. 2015;90:230–234.
   PubMed Web of Science ®Google Scholar
• Friedberg J. Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin’s lymphoma. Haematologica. 2006;91:1453–1455.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Lillington DM, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000;18:947–955.
   PubMed Web of Science ®Google Scholar
• Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:2208–2214.
   PubMed Web of Science ®Google Scholar
• Montoto S, Canals C, Rohatiner AZ, et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007;21:2324–2331.
   PubMed Web of Science ®Google Scholar
• Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol. 1999;106:1020–1026.
   PubMed Web of Science ®Google Scholar
• El-Najjar I, Boumendil A, Luan JJ, et al. The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. Ann Oncol. 2014;25:2224–2229.
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Freedman AS. One size does not fit all in follicular lymphoma. J Clin Oncol. 2013;31:3307–3308.
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Freedman AS. Rethinking prognosis and therapy for follicular lymphoma. J Clin Oncol. 2015;33:2489–2491.
   PubMed Web of Science ®Google Scholar
• Steffanoni S, Ghielmini M, Moccia A. Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options. Expert Rev Anticancer Ther. 2015;15:1337–1349.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Salles G, Bachy E. Chemotherapy-free treatment in patients with follicular lymphoma. Expert Rev Hematol. 2015;8:187–203.
   PubMed Web of Science ®Google Scholar
• Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15:1311–1318.
   PubMed Web of Science ®Google Scholar
• Combined Rituximab and Lenalidomide Treatment for Untreated Patients with Follicular Lymphoma (RELEVANCE). Available from: https://clinicaltrials.gov.
   Google Scholar
• Yang ZZ, Grote DM, Ziesmer SC, et al. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. Blood Cancer J. 2015;5:e281.
   PubMed Web of Science ®Google Scholar
• Chevalier N, Mueller M, Mougiakakos D, et al. Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment. Leuk Lymphoma. 2016;57:2150–2160.
   PubMed Web of Science ®Google Scholar
• Pon JR, Marra MA. Clinical impact of molecular features in diffuse large B-cell lymphoma and follicular lymphoma. Blood. 2016;14:181–186.
   Web of Science ®Google Scholar